Skip To Main Content
BYDUREON Versus Sitagliptin on Muck Rack

BYDUREON Versus Sitagliptin

As seen in: RXLIST®
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with BYDUREON Versus

Contact BYDUREON Versus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Side Effects, Uses, Dosage, Interactions, Warnings

|
By Bydureon BCise, BYDUREON Versus Sitagliptin, John P. Cunha
| RXLIST®
NOTE: January 11, 2024, FDA MedWatch Alert FDA has evaluated reports of suicidal thoughts or actions in patients treated with GLP-1 agonists. Preliminary evaluation has shown no evidence suggesting the use of GLP-1 agonists causes suicidal thoughts or actions. Patients should contact healthcare professional if new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior develops. What Is Bydureon Bcise?
Open in Who Shared Issue with article?

Side Effects, Uses, Dosage, Interactions, Warnings

|
By Keep Bydureon, If Bydureon, Bydureon Pen, BYDUREON Versus Sitagliptin
| RXLIST®
WARNING RISK OF THYROID C-CELL TUMORS Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether Bydureon causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined [see WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].
Open in Who Shared Issue with article?
See all 2 articles